How long was somapacitan in development before FDA approval?

Somapacitan was in development for approximately 13 years, from early 2010s discovery through Phase 1, 2, and 3 trials, culminating in FDA approval in August 2023. The entire clinical trial programme included 21+ studies.

Is somapacitan approved in Europe and Canada?

Yes. The EMA authorised somapacitan on July 28, 2023 (slightly before FDA approval), and Health Canada granted market authorisation in 2024. It is approved and marketed in all three regions under the brand name Sogroya.

What makes somapacitan different from daily growth hormone injections?

Somapacitan is a long-acting hGH analogue requiring once-weekly dosing, compared to daily injections for standard recombinant hGH. The extended half-life is achieved via acylation (fatty acid attachment), which binds to serum albumin and keeps the hormone circulating longer.

Are paediatric trials underway for somapacitan?

Yes. Novo Nordisk is conducting Phase 3 trials in children with growth hormone deficiency as part of its paediatric investigation plan (PIP) commitments. These studies aim to extend approval to younger populations by 2025–2026.

Somapacitan Regulatory History: Timeline & FDA Approval

Q: When was somapacitan approved by the FDA?

The FDA approved somapacitan (Sogroya) on August 28, 2023, for once-weekly subcutaneous injection in adults with growth hormone deficiency. It was the first long-acting GH receptor agonist approved in nearly 19 years.

Somapacitan is a long-acting human growth hormone (hGH) analogue developed by Novo Nordisk that received FDA approval in August 2023 under the brand name Sogroya. It represents a significant advancement in GH replacement therapy, offering once-weekly dosing compared to daily injections required by older treatments. The compound has completed over 21 clinical trials across multiple phases, securing regulatory approval in the US, EU, and Canada—marking the first new GH receptor agonist approved in nearly two decades.

Development & Discovery Phase (2010s)

Somapacitan's development began in the early-to-mid 2010s as part of Novo Nordisk's long-acting peptide programme. The compound was engineered by attaching a fatty acid chain to recombinant human growth hormone, extending its half-life from ~20 minutes (native hGH) to approximately 5–7 days. This chemical modification, called acylation, allows the molecule to bind to serum albumin—a trick that keeps it circulating longer and reduces dosing frequency.

The rationale was straightforward: patients on daily GH therapy often experience variable hormone levels and treatment burden. A once-weekly option could improve compliance and quality of life while maintaining efficacy.

Phase 1 & Early Phase 2 Studies (2015–2018)

Initial human safety and pharmacokinetic studies confirmed somapacitan's extended half-life and favorable tolerability profile. Early Phase 1 data established dose-response relationships and validated the once-weekly concept in healthy volunteers and GH-deficient patients.

These foundational trials paved the way for larger efficacy studies and demonstrated that the albumin-binding approach was safe and reproducible in humans.

Phase 2 Dose-Finding Trials (2018–2020)

Somapacitan entered larger Phase 2 programmes to identify the optimal weekly dose. Multiple trials recruited adults with growth hormone deficiency (GHD) and compared somapacitan against daily recombinant hGH (rGH) and placebo.

Key Phase 2 outcomes demonstrated non-inferior or superior insulin-like growth factor 1 (IGF-1) levels compared to daily hGH, with improved stability of hormone exposure. Adverse event profiles remained consistent with standard GH replacement therapy—headaches, joint pain, and mild fluid retention at expected frequencies.

These results informed the dosing strategy for pivotal Phase 3 trials.

Phase 3 Pivotal Trials & Regulatory Submissions (2019–2022)

Novo Nordisk initiated two primary Phase 3 studies:

REAL 1 (Adults with GHD, naïve to GH therapy): This trial enrolled treatment-naïve adult GHD patients and compared somapacitan once-weekly dosing to daily rGH over 52 weeks. REAL 1 results showed non-inferiority in IGF-1 normalization and body composition improvements, with a favorable safety profile.

REAL 2 (Adults switching from daily GH): This trial included patients already on daily GH therapy who switched to once-weekly somapacitan. Results confirmed efficacy maintenance and improved quality-of-life metrics related to dosing burden.

Across the somapacitan clinical trial programme, over 21 trials evaluated the compound in various populations, including children with GHD (ongoing), adults with adult-onset GHD, and patients with GH deficiency due to pituitary disease.

Based on Phase 3 data, Novo Nordisk submitted a Biologics License Application (BLA) to the FDA in late 2022.

FDA Approval (August 2023)

On August 28, 2023, the FDA granted approval to Sogroya (somapacitan) for once-weekly subcutaneous injection in adults with growth hormone deficiency. This marked the first FDA-approved long-acting GH receptor agonist in 19 years.

The approval was based on demonstrated efficacy in restoring IGF-1 to normal age- and sex-adjusted ranges, improvements in lean body mass, and reductions in fat mass compared to placebo and daily hGH controls.

EMA Authorisation (July 2023)

Somapacitan achieved European Medicines Agency (EMA) authorisation slightly before FDA approval. On July 28, 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Sogroya in the EU for the same indication: once-weekly treatment of adults with growth hormone deficiency.

EMA assessment report confirmed the benefit-risk profile and highlighted the clinical convenience of once-weekly dosing as a major patient-relevant advantage.

Health Canada Approval (2024)

Following US and EU approvals, Health Canada granted market authorisation for Sogroya in early 2024, bringing somapacitan to the Canadian market and reinforcing its global regulatory acceptance.

Key Regulatory Milestones Summary

| Milestone | Date | Regulatory Body | Status | |---|---|---|---| | Phase 1/2 initiation | ~2015 | N/A | Safety & PK confirmed | | Phase 3 REAL 1 & REAL 2 | 2019–2021 | N/A | Non-inferiority demonstrated | | EMA CHMP positive opinion | July 28, 2023 | EMA | Authorisation recommended | | FDA approval | August 28, 2023 | FDA | Approved as Sogroya | | Health Canada approval | 2024 | Health Canada | Market authorisation granted | | Ongoing trials | 2024+ | Various | Paediatric studies continue |

Current Clinical & Regulatory Status

As of 2024, somapacitan is approved and marketed globally under the brand name Sogroya in multiple jurisdictions. The compound is indicated for once-weekly subcutaneous injection in adults with growth hormone deficiency.

Ongoing research includes paediatric GHD trials, which remain in progress under Novo Nordisk's paediatric investigation plan (PIP) commitments to regulatory agencies. These studies aim to extend approval to children—a logical next step given the convenience advantage of once-weekly dosing.

Why Somapacitan Matters for Regulatory Precedent

Somapacitan's approval represents a shift in GH replacement therapy paradigm. For nearly 20 years, daily injections were the standard. Long-acting GH formulations had been attempted (e.g., depot GH) but failed to achieve the same safety and efficacy balance.

Somapacitan succeeded because the albumin-binding acylation strategy proved: (1) reproducible and scalable in manufacturing, (2) safe in humans with no unexpected immunogenicity, and (3) clinically superior in terms of dosing frequency without sacrificing efficacy or safety profiles.

From a regulatory lens, somapacitan's approval signals that the FDA and EMA view once-weekly GH receptor agonists as a legitimate therapeutic advance—setting a precedent for similar long-acting peptide therapeutics in endocrinology and beyond.

Clinical Trial Landscape

With 21 completed or ongoing trials, somapacitan has been one of the most extensively studied long-acting GH formulations. Trial data spans adult and paediatric populations, naive and switching cohorts, and various GHD aetiologies (pituitary disease, genetic deficiency, post-surgical).

This breadth of evidence underpinned the rapid regulatory approvals in 2023 and continues to build the real-world safety and efficacy database post-approval.

Related Compounds & Context

For context, somapacitan joins other long-acting peptide therapeutics approved in recent years, including semaglutide (once-weekly GLP-1 agonist) and tirzepatide (once-weekly dual GIP/GLP-1 agonist). Like somapacitan, these compounds leverage acylation or albumin-binding to extend half-lives and reduce dosing burden.

Tesamorelin, a growth hormone-releasing hormone (GHRH) analogue, remains an older option for GH deficiency but requires daily dosing. Somapacitan's once-weekly profile offers a meaningful improvement in patient convenience compared to tesamorelin and daily rGH.

Glossary of Key Terms

Growth Hormone Deficiency (GHD): A condition in which the pituitary gland fails to produce adequate growth hormone, resulting in metabolic and body composition changes in adults.
Acylation: A chemical modification that attaches a fatty acid chain to a peptide or protein, extending its half-life and circulation time.
IGF-1 (Insulin-Like Growth Factor 1): A hormone mediating many of growth hormone's systemic effects; normalized IGF-1 is the primary efficacy endpoint for GH replacement therapy.

Looking Forward

Somapacitan's regulatory timeline reflects the maturation of long-acting peptide science and manufacturing. Approved in 2023 after ~13 years of development, it signals confidence in acylation as a platform for peptide therapeutics. Future developments may include additional paediatric approvals and expanded indications, pending ongoing trial data.

Somapacitan Regulatory History: From Development to Global Approval